Literature DB >> 2366215

Voluntary control of saccadic eye movements in patients with schizophrenic and affective disorders.

J Fukushima1, N Morita, K Fukushima, T Chiba, S Tanaka, I Yamashita.   

Abstract

We have examined visually guided saccade and antisaccade tasks in 32 schizophrenics, 13 patients with affective disorders and 36 normal controls. Latencies of saccades were within the normal range in all patients examined. In the antisaccade task, 26/32 schizophrenics showed more errors and/or longer latencies, whereas 11/13 patients with affective disorders showed normal results. One manic patient showed significantly longer latency, and one bipolar patient showed a borderline error rate (15%). These results indicate that the antisaccade abnormalities in schizophrenics were not correlated with age, duration of illness, length of education or quantities of medication. None of the schizophrenics with normal antisaccades showed abnormalities in CT scans, while 73% of the schizophrenics who showed both higher error rate and longer latencies showed atrophy of the frontal cortex. The scores of conceptual disorganization and motor retardation in Brief Psychiatric Rating Scale (BPRS) were significantly higher in schizophrenics with abnormal antisaccades, while acute symptoms such as delusions and hallucinations were not correlated with the abnormalities.

Entities:  

Mesh:

Year:  1990        PMID: 2366215     DOI: 10.1016/0022-3956(90)90021-h

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  26 in total

1.  Smooth pursuit and saccadic eye movement performance in a prefrontal leukotomy patient.

Authors:  D C Gooding; W G Iacono; D R Hanson
Journal:  J Psychiatry Neurosci       Date:  1999-11       Impact factor: 6.186

2.  The antisaccade task and neuropsychological tests of prefrontal cortical integrity in schizophrenia: empirical findings and interpretative considerations.

Authors:  Deborah L Levy; Nancy R Mendell; Philip S Holzman
Journal:  World Psychiatry       Date:  2004-02       Impact factor: 49.548

3.  The relationship of saccadic peak velocity to latency: evidence for a new prosaccadic abnormality in schizophrenia.

Authors:  Rajeev S Ramchandran; Dara S Manoach; Mariya V Cherkasova; Kristen A Lindgren; Donald C Goff; Jason J S Barton
Journal:  Exp Brain Res       Date:  2004-07-29       Impact factor: 1.972

4.  Advances in endophenotyping schizophrenia.

Authors:  David L Braff; Tiffany A Greenwood; Neal R Swerdlow; Gregory A Light; Nicholas J Schork
Journal:  World Psychiatry       Date:  2008-02       Impact factor: 49.548

Review 5.  Eye tracking dysfunction in schizophrenia: characterization and pathophysiology.

Authors:  Deborah L Levy; Anne B Sereno; Diane C Gooding; Gilllian A O'Driscoll
Journal:  Curr Top Behav Neurosci       Date:  2010

6.  Response suppression deficits in treatment-naïve first-episode patients with schizophrenia, psychotic bipolar disorder and psychotic major depression.

Authors:  Margret S H Harris; James L Reilly; Michael E Thase; Matcheri S Keshavan; John A Sweeney
Journal:  Psychiatry Res       Date:  2009-11-10       Impact factor: 3.222

7.  Perturbed reward processing in pediatric bipolar disorder: an antisaccade study.

Authors:  Sven C Mueller; Pamela Ng; Veronica Temple; Michael G Hardin; Daniel S Pine; Ellen Leibenluft; Monique Ernst
Journal:  J Psychopharmacol       Date:  2010-01-15       Impact factor: 4.153

8.  Preattentional and attentional cognitive deficits as targets for treating schizophrenia.

Authors:  David L Braff; Gregory A Light
Journal:  Psychopharmacology (Berl)       Date:  2004-04-30       Impact factor: 4.530

9.  Task-switching in schizophrenia: active switching costs and passive carry-over effects in an antisaccade paradigm.

Authors:  Cathleen Greenzang; Dara S Manoach; Donald C Goff; Jason J S Barton
Journal:  Exp Brain Res       Date:  2007-05-08       Impact factor: 1.972

10.  Neurophyisological and neurocognitive endophenotypes for schizophrenia genetics research.

Authors:  Yeon Ho Joo
Journal:  Psychiatry Investig       Date:  2008-12-31       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.